Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Functional characterization of a VEGF-A-targeting Anticalin, prototype of a novel therapeutic human protein class.

Gille H, Hülsmeyer M, Trentmann S, Matschiner G, Christian HJ, Meyer T, Amirkhosravi A, Audoly LP, Hohlbaum AM, Skerra A.

Angiogenesis. 2016 Jan;19(1):79-94. doi: 10.1007/s10456-015-9490-5. Epub 2015 Dec 9.

PMID:
26650228
2.

In vivo visualization of MET tumor expression and anticalin biodistribution with the MET-specific anticalin 89Zr-PRS-110 PET tracer.

Terwisscha van Scheltinga AG, Lub-de Hooge MN, Hinner MJ, Verheijen RB, Allersdorfer A, Hülsmeyer M, Nagengast WB, Schröder CP, Kosterink JG, de Vries EG, Audoly L, Olwill SA.

J Nucl Med. 2014 Apr;55(4):665-71. doi: 10.2967/jnumed.113.124941. Epub 2014 Mar 10.

3.

A highly potent and specific MET therapeutic protein antagonist with both ligand-dependent and ligand-independent activity.

Olwill SA, Joffroy C, Gille H, Vigna E, Matschiner G, Allersdorfer A, Lunde BM, Jaworski J, Burrows JF, Chiriaco C, Christian HJ, Hülsmeyer M, Trentmann S, Jensen K, Hohlbaum AM, Audoly L.

Mol Cancer Ther. 2013 Nov;12(11):2459-71. doi: 10.1158/1535-7163.MCT-13-0318. Epub 2013 Sep 3.

4.

Fab antibodies capable of blocking T cells by competitive binding have the identical specificity but a higher affinity to the MHC-peptide-complex than the T cell receptor.

Neumann F, Sturm C, Hülsmeyer M, Dauth N, Guillaume P, Luescher IF, Pfreundschuh M, Held G.

Immunol Lett. 2009 Aug 15;125(2):86-92. doi: 10.1016/j.imlet.2009.06.002. Epub 2009 Jun 12.

PMID:
19524620
5.

An engineered lipocalin specific for CTLA-4 reveals a combining site with structural and conformational features similar to antibodies.

Schönfeld D, Matschiner G, Chatwell L, Trentmann S, Gille H, Hülsmeyer M, Brown N, Kaye PM, Schlehuber S, Hohlbaum AM, Skerra A.

Proc Natl Acad Sci U S A. 2009 May 19;106(20):8198-203. doi: 10.1073/pnas.0813399106. Epub 2009 May 5.

6.

Thermodynamic and structural equivalence of two HLA-B27 subtypes complexed with a self-peptide.

Hülsmeyer M, Welfle K, Pöhlmann T, Misselwitz R, Alexiev U, Welfle H, Saenger W, Uchanska-Ziegler B, Ziegler A.

J Mol Biol. 2005 Mar 11;346(5):1367-79. Epub 2005 Jan 28.

PMID:
15713487
7.

The solvent-inaccessible Cys67 residue of HLA-B27 contributes to T cell recognition of HLA-B27/peptide complexes.

Appel H, Kuon W, Kuhne M, Hülsmeyer M, Kollnberger S, Kuhlmann S, Weiss E, Zeitz M, Wucherpfennig K, Bowness P, Sieper J.

J Immunol. 2004 Dec 1;173(11):6564-73.

8.

Allele-dependent similarity between viral and self-peptide presentation by HLA-B27 subtypes.

Fiorillo MT, Rückert C, Hülsmeyer M, Sorrentino R, Saenger W, Ziegler A, Uchanska-Ziegler B.

J Biol Chem. 2005 Jan 28;280(4):2962-71. Epub 2004 Nov 10.

9.

A major histocompatibility complex-peptide-restricted antibody and t cell receptor molecules recognize their target by distinct binding modes: crystal structure of human leukocyte antigen (HLA)-A1-MAGE-A1 in complex with FAB-HYB3.

Hülsmeyer M, Chames P, Hillig RC, Stanfield RL, Held G, Coulie PG, Alings C, Wille G, Saenger W, Uchanska-Ziegler B, Hoogenboom HR, Ziegler A.

J Biol Chem. 2005 Jan 28;280(4):2972-80. Epub 2004 Nov 10.

10.

A single residue exchange between two HLA-B27 alleles triggers increased peptide flexibility.

Starikov EB, Nilsson L, Hülsmeyer M.

Eur Biophys J. 2004 Nov;33(7):651-5. Epub 2004 Mar 10. Erratum in: Eur Biophys J. 2004 Nov;33(7):656. Starikow, Ewgeni B [corrected to Starikov, Ewgeni B].

PMID:
15014909
11.

Dual, HLA-B27 subtype-dependent conformation of a self-peptide.

Hülsmeyer M, Fiorillo MT, Bettosini F, Sorrentino R, Saenger W, Ziegler A, Uchanska-Ziegler B.

J Exp Med. 2004 Jan 19;199(2):271-81.

12.

Thermodynamic and structural analysis of peptide- and allele-dependent properties of two HLA-B27 subtypes exhibiting differential disease association.

Hillig RC, Hülsmeyer M, Saenger W, Welfle K, Misselwitz R, Welfle H, Kozerski C, Volz A, Uchanska-Ziegler B, Ziegler A.

J Biol Chem. 2004 Jan 2;279(1):652-63. Epub 2003 Oct 10.

13.

Human CD30: structural implications from epitope mapping and modeling studies.

Dong L, Hülsmeyer M, Dürkop H, Hansen HP, Schneider-Mergener J, Ziegler A, Uchanska-Ziegler B.

J Mol Recognit. 2003 Jan-Feb;16(1):28-36.

PMID:
12557237
14.

HLA-B27 subtypes differentially associated with disease exhibit subtle structural alterations.

Hülsmeyer M, Hillig RC, Volz A, Rühl M, Schröder W, Saenger W, Ziegler A, Uchanska-Ziegler B.

J Biol Chem. 2002 Dec 6;277(49):47844-53. Epub 2002 Sep 18.

15.

Structure of interleukin 4 mutant E9A suggests polar steering in receptor-complex formation.

Hülsmeyer M, Scheufler C, Dreyer MK.

Acta Crystallogr D Biol Crystallogr. 2001 Sep;57(Pt 9):1334-6. Epub 2001 Aug 23.

PMID:
11526337
16.

High-resolution structure of HLA-A*0201 in complex with a tumour-specific antigenic peptide encoded by the MAGE-A4 gene.

Hillig RC, Coulie PG, Stroobant V, Saenger W, Ziegler A, Hülsmeyer M.

J Mol Biol. 2001 Jul 27;310(5):1167-76.

PMID:
11502003
17.

Crystal structure of human bone morphogenetic protein-2 at 2.7 A resolution.

Scheufler C, Sebald W, Hülsmeyer M.

J Mol Biol. 1999 Mar 19;287(1):103-15.

PMID:
10074410
18.

Crystal structure of cis-biphenyl-2,3-dihydrodiol-2,3-dehydrogenase from a PCB degrader at 2.0 A resolution.

Hülsmeyer M, Hecht HJ, Niefind K, Hofer B, Eltis LD, Timmis KN, Schomburg D.

Protein Sci. 1998 Jun;7(6):1286-93.

Supplemental Content

Loading ...
Support Center